文献速递妇科

宫颈癌水平与环周肿瘤范围的预后作用:对2019 FIGO分期的启示

The prognostic role of horizontal and circumferential tumor extent in cervical cancer: Implications for the 2019 FIGO staging system.
PubMed 文献 · Gynecol Oncol · 2020-05-26

该单中心回顾性研究纳入285例接受初次手术的I期宫颈癌患者,中位随访48个月,分析水平肿瘤范围(HZTE)和环周肿瘤范围(%CTE)与生存结局的关联。结果显示HZTE是生存的独立预测因子,但在IA期肿瘤中不提供额外预后价值,支持2019 FIGO分期将其从分期变量中移除;%CTE不是独立预后变量。

要点

  • HZTE是宫颈癌生存的独立预测因子,但在IA期肿瘤中无额外预后价值。
  • 168例IA期患者(含42例HZTE≥7 mm)随访期间均无复发或死亡。
  • %CTE仅单因素分析与无复发生存相关,不建议作为预后变量使用。

核心结论

  • HZTE是宫颈癌生存的独立预测因子,但在IA期肿瘤中不提供优于分期的预后价值,支持2019 FIGO建议将其从分期中移除。
  • HZTE可能在分期依赖最大肿瘤尺寸的较大肿瘤中有用。
  • %CTE不是宫颈癌的独立预后变量,建议不使用。

研究设计与样本

  • 单中心回顾性研究,纳入9年间接受初次手术的I期宫颈癌患者285例,中位随访48个月(范围7-123个月),按2019 FIGO分期。

主要发现

  • HZTE在单因素和多因素分析中均与无复发生存(RFS)和疾病特异性生存(DSS) statistically 相关。
  • 168例IA期患者随访期间均无肿瘤复发或死亡,包括42例HZTE≥7 mm者;HZTE<7 mm者也无复发或死亡。
  • %CTE仅在单因素分析与RFS相关。
  • 2019 FIGO分期在本样本中未独立相关于RFS或DSS。

临床怎么用

  • 对于IA期宫颈癌,无需将HZTE作为分期或预后判断的独立依据。
  • 在较大肿瘤中,若分期依赖最大肿瘤尺寸,可考虑评估HZTE的预后信息。
  • 不建议将%CTE用于宫颈癌的预后评估。

局限性

  • 单中心回顾性研究,样本量285例,部分患者%CTE数据可能不可得。
  • 2019 FIGO分期在本样本中未独立相关于生存结局,可能影响结论外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The FIGO 2019 update on cervical cancer staging removed horizontal tumor extent (HZTE) as a staging variable. Evidence is needed to substantiate this change. The prognostic significance of HZTE and a related variable, circumferential tumor extent (%CTE), is similarly unknown. We aimed to investigate the association of HZTE and %CTE with survival outcomes in cervical cancer patients. METHODS: We identified patients treated with primary surgery for stage I cervical cancer in a single institution during a 9-year period. HZTE and, when available, %CTE were obtained from pathology records. Cases were staged using 2019 FIGO staging. Correlations between HZTE, %CTE and FIGO stage with recurrence-free (RFS) and disease-specific survival (DSS) were determined using univariable and multivariable analyses. RESULTS: 285 patients were included with a median follow-up of 48 (range 7-123) months. HZTE was statistically associated with RFS and DSS on univariate and multivariate analysis. None of the 168 stage IA patients in our series had tumor recurrence or death during follow-up, including 42 with HZTE ≥7 mm. None of the patients with a tumor horizontal extent <7 mm experienced recurrence or death. %CTE correlated only with RFS on univariate analysis. 2019 FIGO stage did not independently correlate with RFS or DSS in our sample. CONCLUSIONS: HZTE is an independent predictor of survival in cervical carcinoma. In stage IA tumors, however, HZTE does not offer superior prognostic value, supporting the 2019 FIGO recommendations to remove this variable from staging in these cases. HZTE may be useful in larger tumors in which staging depends on maximum tumor size. %CTE is not an independent prognostic variable in cervical cancer, and we advise against its use.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Zyla RE, Gien LT, Vicus D, et al. The prognostic role of horizontal and circumferential tumor extent in cervical cancer: Implications for the 2019 FIGO staging system. Gynecol Oncol. 2020. PMID: 32471646. doi:10.1016/j.ygyno.2020.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。